MK-4830

DB17454InvestigationalProtein Based Therapies

MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

Mechanism: Pharmacologically active on Leukocyte immunoglobulin-like receptor subfamily B member 2
Curator reviewed
Code names: MK-4830

Resolves to

Targets

What you can answer from here — as of October 10, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with MK-4830, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.